Title : Low-Dose Triptolide Enhanced Activity of Idarubicin Against Acute Myeloid Leukemia Stem-like Cells Via Inhibiting DNA Damage Repair Response.

Pub. Date : 2021 Apr

PMID : 33078278






4 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Our results showed that low-dose Triptolide (TPL) enhanced the anti-AML activity of Idarubicin (IDA) in vitro against LSC-like cells (CD34 + CD38- KG1alphaand CD34 + CD38- kasumi-1 cells) and CD34+ primary AML cells, while sparing normal cells. Idarubicin CD38 molecule Homo sapiens
2 Our results showed that low-dose Triptolide (TPL) enhanced the anti-AML activity of Idarubicin (IDA) in vitro against LSC-like cells (CD34 + CD38- KG1alphaand CD34 + CD38- kasumi-1 cells) and CD34+ primary AML cells, while sparing normal cells. Idarubicin CD38 molecule Homo sapiens
3 Our results showed that low-dose Triptolide (TPL) enhanced the anti-AML activity of Idarubicin (IDA) in vitro against LSC-like cells (CD34 + CD38- KG1alphaand CD34 + CD38- kasumi-1 cells) and CD34+ primary AML cells, while sparing normal cells. Idarubicin CD38 molecule Homo sapiens
4 Our results showed that low-dose Triptolide (TPL) enhanced the anti-AML activity of Idarubicin (IDA) in vitro against LSC-like cells (CD34 + CD38- KG1alphaand CD34 + CD38- kasumi-1 cells) and CD34+ primary AML cells, while sparing normal cells. Idarubicin CD38 molecule Homo sapiens